Cardiovascular Devices
The U.S. cardiovascular device market is driven by the rising prevalence of heart disease, rapid technological innovation, and favorable reimbursement policies. Our research provides actionable insights into market size, product innovations, competitive landscape, regulatory trends, and future opportunities shaping the cardiovascular care industry.
The U.S. Percutaneous Coronary Intervention Devices Market is poised to expand from USD 5.92 billion in 2026 to USD 8.86 billion by 2032, advancing at a 6.95% CAGR. Growth is fueled by high-acuity calcified lesions, widespread transradial adoption, clinical guideline mandates for intravascular imaging, and the strategic migration of elective revascularization procedures into outpatient departments and ambulatory surgical centers.
Read Report Details
The U.S. AI-enabled cardiovascular devices market is set to expand from USD 6.45 billion in 2026 to USD 16.85 billion by 2032, achieving a 17.36% CAGR. Market growth is propelled by expanding CPT reimbursement, persistent clinical staffing shortages, and high adoption of deep-learning echocardiography, algorithmic ECG patches, smart implantable rhythm platforms, and AI-guided catheterization systems across acute hospital networks and outpatient surgical centers.
Read Report Details
The U.S. Implantable Cardiovascular Devices Market is projected to grow from USD 23.05 billion in 2026 to USD 36.18 billion by 2032 at a 7.81% CAGR. Growth is driven by an aging demographic, rising heart failure and arrhythmia incidence, rapid clinical transitions toward minimally invasive transcatheter valves and leadless pacemakers, and expanding reimbursement across outpatient and ambulatory surgical centers.
Read Report Details
The U.S. Minimally Invasive Cardiovascular Devices Market is projected to expand from USD 14.65 billion in 2026 to USD 24.88 billion by 2032, advancing at a 9.22% CAGR. Growth is driven by rapid adoption of transcatheter structural heart replacements, pulsed field ablation systems, intravascular lithotripsy, and the high-volume clinical migration toward outpatient cardiovascular ambulatory surgery centers nationwide.
Read Report Details
The U.S. Cardiovascular Surgical Devices Market is projected to expand from USD 8.89 billion in 2026 to USD 14.12 billion by 2032, advancing at an 8.02% CAGR. Growth is driven by an aging population with complex cardiovascular disease, cardiopulmonary bypass equipment fleet modernizations, expanding robotic-assisted procedures, and surging clinical adoption of advanced structural heart valve repairs and mechanical circulatory support systems.
Read Report Details
The U.S. cardiac monitoring devices market is projected to reach USD 15.48 billion by 2032, expanding at a 7.91% CAGR from USD 9.78 billion in 2026. Growth is propelled by rising atrial fibrillation prevalence, favorable remote patient monitoring reimbursements, nursing labor shortages, and rapid clinical adoption of patch-based wearable biosensors, mobile cardiac telemetry, and artificial intelligence-driven rhythm analytics.
Read Report Details
The U.S. cardiac rhythm management devices market is projected to expand from USD 10.16 billion in 2026 to USD 15.34 billion by 2032 at a 7.10% CAGR. Growth is driven by an aging population with conduction disorders, rapid uptake of dual-chamber leadless pacemakers and extravascular ICDs, left bundle branch area pacing, and procedural migration into ambulatory surgical centers.
Read Report Details
The U.S. Electrophysiology Devices Market is projected to expand from USD 5.52 billion in 2026 to USD 11.28 billion by 2032, registering a 12.65% CAGR. Accelerated by non-thermal pulsed field ablation adoption, high-density 3D mapping integration, and expanding outpatient volume, the sector addresses increasing atrial fibrillation and complex ventricular arrhythmia burdens across U.S. cardiac care facilities.
Read Report Details
The U.S. structural heart devices market is projected to expand from USD 8.62 billion in 2026 to USD 16.48 billion by 2032, advancing at an 11.41% CAGR. Growth is driven by expanding TAVR indications into low-risk cohorts, commercial breakthroughs in transcatheter tricuspid and mitral repairs, rising LAAO adoption, and widespread clinical migration toward minimalist, catheter-based cardiovascular workflows.
Read Report Details
The U.S. Interventional Cardiology Devices Market is set to expand from USD 8.32 billion in 2026 to USD 14.15 billion by 2032 at a 9.25% CAGR. Expansion is propelled by over 600,000 annual PCIs, surging calcified lesion complexity, rapid adoption of intravascular lithotripsy, transradial access migration, and increasing utilization of coronary drug-coated balloons across hospital cath labs and outpatient surgical centers.
Read Report Details